Regulatory · Tinnitus← The news desk

✦ The Dispatch

FDA approves BosSTENT trial for pulsatile tinnitus

A dispatch from Hearing Practitioner Australia — filed

Young woman with eyes closed pressing both hands against her ears, grimacing in discomfort, seated indoors
✦ PlateYoung woman with eyes closed pressing both hands against her ears, grimacing in discomfort, seated indoors

Venous sinus stenosis is the most common cause of pulsatile tinnitus, which can be severely disabling. Image: Sebra/stock.adobe.com. Sonorous Neurovascular has received US Food and Drug Administration (FDA) approval to begin a pivotal trial of a purpose-built stent for treating pulsatile tinnitus caused by venous sinus stenosis....

Continue reading at Hearing Practitioner Australia

✦ The floor

Discussion

Signed responses from readers of the wire.

✦ Clinical Takeaway ✦

No actionable change for audiologists at this stage — the trial has only received FDA approval to begin; no efficacy or safety data are yet available. Audiologists managing pulsatile tinnitus patients may wish to monitor this trial's progress.

✦ Why It Matters ✦

If the BosSTENT pivotal trial succeeds, it could establish the first purpose-built interventional device for venous sinus stenosis–related pulsatile tinnitus, expanding the treatment pathway beyond audiology into neurovascular care.

✦ Key Points ✦
  1. 01FDA has approved Sonorous Neurovascular to begin a pivotal (large, definitive) clinical trial of the BosSTENT.
  2. 02The BosSTENT is specifically designed to treat pulsatile tinnitus caused by venous sinus stenosis (narrowing of a vein near the brain).
  3. 03This is a regulatory milestone — no trial results or safety/efficacy data have been reported yet.
  4. 04Pulsatile tinnitus is a subset of tinnitus with an identifiable vascular cause, distinct from the more common non-pulsatile form.
  5. 05The device targets a gap in current treatment options for this specific tinnitus subtype.
✦ Claims & Evidence ✦

The BosSTENT is a purpose-built stent designed to treat pulsatile tinnitus caused by venous sinus stenosis.

press releaseunclear

The FDA has approved Sonorous Neurovascular to begin a pivotal clinical trial of the BosSTENT.

press releasesupported
✦ Related stories ✦